Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$118.30

-0.99 (-0.83%)

, NBIX

Neurocrine

$90.59

-1.84 (-1.99%)

08:03
03/13/18
03/13
08:03
03/13/18
08:03

AbbVie says Phase 3 ELARIS UF-II study of elagolix met primary endpoint

AbbVie (ABBV) in cooperation with Neurocrine Biosciences (NBIX), announced that the Phase 3 ELARIS UF-II study of elagolix met its primary endpoint. Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone therapy, reduced heavy menstrual bleeding with 76.2% of women with uterine fibroids achieving clinical response compared to placebo, as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50% or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints at month six.

ABBV

AbbVie

$118.30

-0.99 (-0.83%)

NBIX

Neurocrine

$90.59

-1.84 (-1.99%)

  • 13

    Mar

  • 13

    Mar

  • 20

    Mar

ABBV AbbVie
$118.30

-0.99 (-0.83%)

02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Overweight
Piper says 'hard to quibble with' elagolix efficacy, keeps AbbVie at Overweight
After AbbVie reported that one of its two Phase 3 trials of elagolix in patients with uterine fibroids met its primary efficacy endpoint and all ranked secondary endpoints, Piper Jaffray analyst Christopher Raymond said it was "hard to quibble with the efficacy data." He expects to see 12-month data from both trials later this year or early next, which would set up for a potential uterine fibroids launch in 2020. Raymond, who said he "would not be shocked" if his revenue estimates in this indication prove conservative, keeps an Overweight rating on AbbVie.
02/22/18
NEED
02/22/18
NO CHANGE
Target $110
NEED
Buy
Neurocrine price target raised to $110 from $95 at Needham
Needham analyst Alan Carr raised his price target on Neurocrine (NBIX) to $110 and kept his Buy rating on the stock. Carr cites the positive top-line results from the first of two phase 3 trials of elagolix by Neurocrine's collaborator AbbVie (ABBV) as well as last week's disclosure that the FDA will not require another phase 3 efficacy trial for opicapone. The analyst notes that the added timeline clarity will likely translate into the opicapone NDA submission in the first half of 2019 and a launch in mid-2020.
02/23/18
OPCO
02/23/18
NO CHANGE
Target $110
OPCO
Outperform
Neurocrine 'going for gold,' has 'Midas Touch,' says Oppenheimer
Oppenheimer analyst Jay Olson raised his price target on Neurocrine shares to $110 from $100, citing the positive Phase 3 study results for elagolix in the treatment of uterine fibroids by Neurocrine's collaborator AbbVie (ABBV). Additionally, Olson cited last week's disclosure that the FDA will not require a Phase 3 study in the U.S. for opicapone for the price target increase. Olson told investors in a research note called "Going for Gold -- This Team Has the Midas Touch" that both of these updates are seen as "key de-risking events" and raise the probability of success for both elagolix and opicapone to 90% from 60%. Olson has an Outperform rating on Neurocrine shares.
03/08/18
PIPR
03/08/18
NO CHANGE
Target $138
PIPR
Overweight
AbbVie shares can 'continue to work,' says Piper Jaffray
After hosting a meeting with investors at AbbVie's (ABBV) headquarters this week, Piper Jaffray analyst Christopher Raymond believes the shares can "continue to work." The analyst believes the stock can continue outperforming on "solid" commercial and clinical performance. Management expressed no urgency for a larger commercial or late-stage acquisition, Raymond tells investors in a research note. The analyst says he's glad he never wrote that AbbVie for Biogen (BIIB) research note. He keeps an Overweight rating on AbbVie.
NBIX Neurocrine
$90.59

-1.84 (-1.99%)

02/14/18
OPCO
02/14/18
NO CHANGE
Target $100
OPCO
Outperform
Neurocrine price target raised to $100 from $95 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $100 from $95 to reflect Q4 financial results, management guidance on expenses and profitability. The analyst reiterates an Outperform rating on the shares.
02/20/18
LEER
02/20/18
NO CHANGE
Target $96
LEER
Outperform
Neurocrine price target raised to $96 from $90 at Leerink
Leerink analyst Paul Matteis raised his price target Neurocrine to $96 from $90 to reflect the company's positive update on opicapone, Q4 results, and bullish commentary from management at his firm recent investor dinner. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AAPL

Apple

$205.28

-1.82 (-0.88%)

09:39
04/26/19
04/26
09:39
04/26/19
09:39
Recommendations
Apple analyst commentary  »

Apple incentives not much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    Jun

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

, TSCO

Tractor Supply

$105.09

1 (0.96%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Hibbett Sports names Christine Skold as Interim CFO, effective April 26 »

Hibbett Sports (HIBB)…

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

TSCO

Tractor Supply

$105.09

1 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

  • 23

    May

  • 25

    Jul

  • 13

    Nov

SBUX

Starbucks

$77.07

0.65 (0.85%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Starbucks CEO says competitor discounts in China not sustainable »

Kevin Johnson is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$161.03

-0.47 (-0.29%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
Visa analyst commentary at BMO Capital »

Visa price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

WNS

WNS Holdings

$56.71

0.26 (0.46%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
WNS Holdings analyst commentary  »

WNS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ANTM

Anthem

$256.01

5 (1.99%)

, CVS

CVS Health

$53.24

0.31 (0.59%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Recommendations
Anthem, CVS Health analyst commentary at Cleveland Research »

Anthem won Blue Cross of…

ANTM

Anthem

$256.01

5 (1.99%)

CVS

CVS Health

$53.24

0.31 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 15

    May

  • 16

    May

  • 19

    May

  • 29

    May

  • 18

    Jun

RL

Ralph Lauren

$129.74

-2.31 (-1.75%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Upgrade
Ralph Lauren rating change  »

Ralph Lauren upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SFLY

Shutterfly

$42.30

-0.65 (-1.51%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Upgrade
Shutterfly rating change  »

Shutterfly upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

HTBK

Heritage Commerce

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Downgrade
Heritage Commerce rating change  »

Heritage Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

SIVB

SVB Financial

$247.10

-1.84 (-0.74%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Downgrade
SVB Financial rating change  »

SVB Financial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

  • 09

    May

MAS

Masco

$37.50

-2.48 (-6.20%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Upgrade
Masco rating change  »

Masco upgraded two levels…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

FLGT

Fulgent Genetics

$7.23

-0.02 (-0.28%)

09:31
04/26/19
04/26
09:31
04/26/19
09:31
Downgrade
Fulgent Genetics rating change at Credit Suisse »

Fulgent Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

09:30
04/26/19
04/26
09:30
04/26/19
09:30
Recommendations
Pros Holdings analyst commentary  »

ProsHoldings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

CLS

Celestica

$7.29

-1.315 (-15.28%)

09:28
04/26/19
04/26
09:28
04/26/19
09:28
Downgrade
Celestica rating change at Canaccord »

Celestica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$451.24

-6.61 (-1.44%)

09:27
04/26/19
04/26
09:27
04/26/19
09:27
Conference/Events
Sherwin-Williams management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

CARO

Carolina Financial

$36.08

-0.83 (-2.25%)

09:26
04/26/19
04/26
09:26
04/26/19
09:26
Downgrade
Carolina Financial rating change  »

Carolina Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGO

Argo Group

$74.21

-0.245 (-0.33%)

09:26
04/26/19
04/26
09:26
04/26/19
09:26
Upgrade
Argo Group rating change at William Blair »

Argo shares could double…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 11

    Jun

POWI

Power Integrations

$78.11

-1.93 (-2.41%)

09:25
04/26/19
04/26
09:25
04/26/19
09:25
Recommendations
Power Integrations analyst commentary at Loop Capital »

Power Integrations price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 22

    May

HPE

HP Enterprise

$16.00

-0.27 (-1.66%)

09:25
04/26/19
04/26
09:25
04/26/19
09:25
Conference/Events
HP Enterprise management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 09

    Jul

09:25
04/26/19
04/26
09:25
04/26/19
09:25
General news
Today's U.S. GDP report »

Today's U.S. GDP…

HFWA

Heritage Financial

$30.77

-0.6 (-1.91%)

09:23
04/26/19
04/26
09:23
04/26/19
09:23
Downgrade
Heritage Financial rating change at Sandler ONeill »

Heritage Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

TAL

TAL Education

$36.22

1.81 (5.26%)

09:22
04/26/19
04/26
09:22
04/26/19
09:22
Upgrade
TAL Education rating change  »

TAL Education upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:20
04/26/19
04/26
09:20
04/26/19
09:20
General news
Fed funds futures are in rally mode »

Fed funds futures are in…

INTC

Intel

$57.59

-1.13 (-1.92%)

, AMD

AMD

$27.66

-0.8 (-2.81%)

09:19
04/26/19
04/26
09:19
04/26/19
09:19
Recommendations
Intel, AMD, Nvidia, Seagate, Western Digital, Micron analyst commentary  »

Intel report positive for…

INTC

Intel

$57.59

-1.13 (-1.92%)

AMD

AMD

$27.66

-0.8 (-2.81%)

NVDA

Nvidia

$186.84

-4.35 (-2.28%)

STX

Seagate

$46.09

-0.9 (-1.92%)

WDC

Western Digital

$52.95

-1.03 (-1.91%)

MU

Micron

$42.76

-0.27 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 30

    Apr

  • 30

    Apr

  • 08

    May

  • 15

    May

  • 16

    May

  • 22

    May

  • 03

    Jun

  • 06

    Jun

  • 10

    Jun

  • 25

    Jul

SK

Slack Technologies

$0.00

(0.00%)

09:19
04/26/19
04/26
09:19
04/26/19
09:19
Syndicate
Slack Technologies files direct listing on NYSE under symbol 'SK' »

Slack Technologies filed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.